ICU Medical (NASDAQ:ICUI) Rating Lowered to “Hold” at Wall Street Zen

ICU Medical (NASDAQ:ICUI) was downgraded by Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued on Sunday.

Other equities research analysts also recently issued research reports about the company. Weiss Ratings restated a “sell (d-)” rating on shares of ICU Medical in a report on Wednesday, October 8th. KeyCorp upped their price objective on shares of ICU Medical from $173.00 to $175.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. Finally, Piper Sandler lifted their price objective on shares of ICU Medical from $153.00 to $172.00 and gave the company an “overweight” rating in a report on Friday, November 7th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $175.67.

ICU Medical Stock Performance

ICUI stock opened at $151.19 on Friday. The firm has a market cap of $3.73 billion, a PE ratio of -487.69 and a beta of 0.80. The company has a current ratio of 2.45, a quick ratio of 1.19 and a debt-to-equity ratio of 0.62. The stock has a 50-day moving average price of $143.66 and a 200-day moving average price of $131.61. ICU Medical has a 1-year low of $107.00 and a 1-year high of $175.51.

ICU Medical (NASDAQ:ICUI) last issued its earnings results on Thursday, November 6th. The medical instruments supplier reported $2.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.43 by $0.60. ICU Medical had a negative net margin of 0.32% and a positive return on equity of 7.71%. The business had revenue of $533.30 million for the quarter, compared to analyst estimates of $511.46 million. During the same period in the prior year, the firm earned $1.59 earnings per share. ICU Medical’s revenue was down 8.9% on a year-over-year basis. ICU Medical has set its FY 2025 guidance at 7.350-7.650 EPS. As a group, equities research analysts expect that ICU Medical will post 4.11 earnings per share for the current year.

Insider Activity

In other ICU Medical news, VP Virginia Ruth Sanzone sold 930 shares of ICU Medical stock in a transaction dated Tuesday, November 11th. The shares were sold at an average price of $142.34, for a total value of $132,376.20. Following the sale, the vice president owned 5,456 shares of the company’s stock, valued at approximately $776,607.04. The trade was a 14.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Elisha W. Finney sold 1,285 shares of ICU Medical stock in a transaction that occurred on Tuesday, November 11th. The stock was sold at an average price of $140.42, for a total transaction of $180,439.70. Following the completion of the sale, the director directly owned 3,995 shares in the company, valued at $560,977.90. This trade represents a 24.34% decrease in their position. The SEC filing for this sale provides additional information. 1.50% of the stock is currently owned by insiders.

Institutional Trading of ICU Medical

A number of large investors have recently bought and sold shares of the company. Cullen Frost Bankers Inc. purchased a new position in shares of ICU Medical during the 2nd quarter valued at $38,000. SJS Investment Consulting Inc. lifted its holdings in ICU Medical by 41,000.0% during the third quarter. SJS Investment Consulting Inc. now owns 411 shares of the medical instruments supplier’s stock valued at $49,000 after purchasing an additional 410 shares during the last quarter. Covestor Ltd boosted its position in ICU Medical by 70.7% during the third quarter. Covestor Ltd now owns 570 shares of the medical instruments supplier’s stock worth $68,000 after purchasing an additional 236 shares during the period. Blue Trust Inc. lifted its stake in shares of ICU Medical by 17.6% during the 2nd quarter. Blue Trust Inc. now owns 942 shares of the medical instruments supplier’s stock valued at $124,000 after buying an additional 141 shares in the last quarter. Finally, Smartleaf Asset Management LLC boosted its holdings in shares of ICU Medical by 11.6% in the second quarter. Smartleaf Asset Management LLC now owns 969 shares of the medical instruments supplier’s stock worth $128,000 after acquiring an additional 101 shares during the period. 96.10% of the stock is owned by hedge funds and other institutional investors.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.